Sarcoma News

The FDA has announced several decisions related to hematology and oncology treatments in the past 2 weeks.

The FDA granted accelerated approval to olaratumab injection for use in combination with doxorubicin to treat adults with soft tissue sarcoma.

Treatment with pomalidomide induced rapid responses in patients with Kaposi sarcoma, regardless of their HIV status, according to study results published in Journal of Clinical Oncology.

COPENHAGEN, Denmark — Neoadjuvant chemotherapy with three full-dose courses of an anthracycline plus ifosfamide improved OS and RFS compared with histology-tailored regimens in patients with localized soft tissue sarcoma at high risk for relapse, according to interim results of a randomized trial presented at the European Society for Medical Oncology Congress.

Survivors of sarcoma demonstrated an increased risk for second malignant neoplasms, according to study results published in Cancer. Survivors of fusion-negative tumors faced a greater risk than those with fusion-positive tumors.

Extraordinary therapeutic advances, a renewed bipartisan commitment to medical research and the launch of the national cancer moonshot initiative have reinforced the importance of scientific investigation in the fight against cancer.

Vice President Joe Biden outlined a plan to improve the efficiency and transparency of the U.S. clinical research system as part of the national cancer moonshot initiative.

The U.S. death rate of children and adolescents with cancer continues to decline with a 20% drop over a 15-year span, according to a data brief report from the CDC’s National Center for Health Statistics.

More than one-half of patients with sarcoma harbored putatively pathogenic monogenic and polygenic mutations to known cancer genes, according to study results published in The Lancet Oncology.

The national cancer moonshot initiative’s blue ribbon panel delivered 10 recommendations to form a 5-year research blueprint to accelerate progress against cancer at the NCI’s National Cancer Advisory Board meeting.